Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of UGN-102 in low-grade intermediate-risk non-muscle-invasive bladder cancer
2023-506680-34-00Phase 3Authorised
- Sponsor
- UroGen Pharma
- Start
- Mar 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of zusduri in non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Primary endpoint: Complete response rate at 3 months. Planned start Mar 2022; status: authorised.
02
Drugs
zusduri
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2023-506680-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506680-34-00.